Damora Therapeutics (DMRA) Enterprise Value (2019 - 2026)
Damora Therapeutics (DMRA) posted Enterprise Value of -$202.4 million for Q1 2026, up 21.44% on a QoQ basis from -$257.6 million in Q4 2025, and down 3280.03% year-over-year from $6.4 million in Q1 2025.
Damora Therapeutics (DMRA) Enterprise Value (2019 - 2026) Analysis & Trends
Damora Therapeutics' Enterprise Value history runs 8 years deep, the most recent figure standing at -$202.4 million for Q1 2026.
- Quarterly Enterprise Value fell 3280.03% year-over-year to -$202.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$202.4 million (down 3280.03% YoY) and the FY2025 annual result came in at -$257.6 million, down 1717.45% from the prior year.
- Enterprise Value was -$202.4 million for Q1 2026 at Damora Therapeutics, up from -$257.6 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$6.0 million in Q1 2025 and bottomed at -$257.6 million in Q4 2025.
- A 5-year average of -$67.2 million and a median of -$52.1 million in 2023 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2025 — Enterprise Value jumped 77.96% — and 2026, when it slumped 3280.03%.
- Damora Therapeutics' Enterprise Value stood at -$60.2 million in 2022, then jumped by 38.59% to -$37.0 million in 2023, then soared by 61.67% to -$14.2 million in 2024, then tumbled by 1717.45% to -$257.6 million in 2025, then increased by 21.44% to -$202.4 million in 2026.
- Business Quant data shows DMRA's Enterprise Value at -$202.4 million in Q1 2026, -$257.6 million in Q4 2025, and -$7.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -1.91 Bn |
| 10 | Damora Therapeutics | 1.00 Bn | 798.11 Mn | - | -202.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -202.40 Mn |
| Dec 31, 2025 | -257.62 Mn |
| Sep 30, 2025 | -7.61 Mn |
| Jun 30, 2025 | -10.21 Mn |
| Mar 31, 2025 | -5.99 Mn |
| Dec 31, 2024 | -14.18 Mn |
| Sep 30, 2024 | -19.70 Mn |
| Jun 30, 2024 | -12.73 Mn |
| Mar 31, 2024 | -27.17 Mn |
| Dec 31, 2023 | -36.98 Mn |
| Sep 30, 2023 | -61.05 Mn |
| Jun 30, 2023 | -52.12 Mn |
| Mar 31, 2023 | -53.25 Mn |
| Dec 31, 2022 | -60.22 Mn |
| Sep 30, 2022 | -101.49 Mn |
| Jun 30, 2022 | -126.89 Mn |
| Mar 31, 2022 | -93.60 Mn |
| Dec 31, 2021 | -100.19 Mn |
| Sep 30, 2021 | -102.14 Mn |
| Jun 30, 2021 | -101.81 Mn |